Company research
JUPITER NEUROSCIENCES, INC.
CIK 1679628Updated Sep 26, 2026
SecurityJUNS · NASDAQ · equity
Name history
Jupiter Orphan Therapeutics, Inc. · through Dec 5, 2017
JUNS price & chart
Loading TradingView…
NASDAQ:JUNS on TradingView ↗In the news
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million ↗
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million ↗
Recent filings
S-3 filing
SCHEDULE 13G filing
D filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other Events
Items 3.01, 8.01, 9.01
Show 5 more recent filings
Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 1.01, 5.02, 8.01, 9.01
Other Events
Items 8.01, 9.01
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other Events
Items 1.01, 3.02, 8.01, 9.01
424B5 filing
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 5,564,030Source | 6,202,409Source | 148,592Source |
| Current assets: | |||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 2,637Source | — | — |
| Inventory, NetUSD | 159,790Source | — | — |
| Assets, CurrentUSD | 4,824,978Source | 4,650,263Source | 28,739Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | 114,086Source | 261Source |
| Operating Lease, Right-of-Use AssetUSD | 23,214Source | 69,642Source | 116,070Source |
| Other Assets, NoncurrentUSD | 3,783Source | 3,783Source | 3,783Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 7,395,882Source | 2,030,401Source | 5,949,946Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 3,444Source | 3,310Source | 2,652Source |
| Additional Paid in CapitalUSD | 32,831,730Source | 30,190,827Source | 17,778,498Source |
| Retained Earnings (Accumulated Deficit)USD | -34,667,026Source | -26,022,129Source | -23,582,504Source |
| Stockholders' Equity Attributable to ParentUSD | -1,831,852Source | 4,172,008Source | -5,801,354Source |
| Liabilities and EquityUSD | 5,564,030Source | 6,202,409Source | 148,592Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 7,395,882Source | 2,009,154Source | 5,771,905Source |
| Operating Lease, Liability, CurrentUSD | 21,247Source | 50,082Source | 48,213Source |
| Operating Lease, Liability, NoncurrentUSD | — | 21,247Source | 71,329Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,418,516Source | 1,840,908Source | 1,198,579Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts ReceivableUSD | 2,637Source | — | — |
| Increase (Decrease) in InventoriesUSD | 159,790Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -5,413,736Source | -3,911,004Source | -480,953Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 5,433,568Source | 7,652,036Source | 445,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 19,832Source | 3,741,032Source | -35,953Source |
| Supplemental disclosure of cash flow information: | |||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 147,776Source | 28,128Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | — | 114,373Source | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | 281,932Source | — | — |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | -53,257Source | 148,751Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | 857,723Source | -887,946Source |
| General and Administrative ExpenseUSD | 6,839,712Source | 2,598,622Source | 2,915,978Source |
| InterestExpenseNonoperatingUSD | 66,020Source | 248,366Source | 218,705Source |
| Investment Income, InterestUSD | — | 5,557Source | 482Source |
| Net Income (Loss) Attributable to ParentUSD | -8,644,897Source | -2,439,625Source | -4,783,689Source |
| Nonoperating Income (Expense)USD | 263,824Source | 651,657Source | -912,918Source |
| Operating ExpensesUSD | 8,926,286Source | 3,091,282Source | 3,870,771Source |
| Proceeds from Issuance of Common StockUSD | — | 150,000Source | 55,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 21,796Source | — | — |
| Stock or Unit Option Plan ExpenseUSD | 697,835Source | 355,829Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | 21,796Source | — | — |
| Cost of RevenueUSD | 4,231Source | — | — |
| Selling, General and Administrative ExpenseUSD | 6,839,712Source | — | — |
| Operating Income (Loss)USD | -8,908,721Source | -3,091,282Source | -3,870,771Source |
| Net Income (Loss) Attributable to ParentUSD | -8,644,897Source | -2,439,625Source | -4,783,689Source |
| Earnings Per Share, BasicUSD per share | -0.25Source | -0.08Source | -0.18Source |
| Earnings Per Share, DilutedUSD per share | -0.25Source | -0.08Source | -0.18Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 34,628,588Source | 28,783,045Source | 26,405,109Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 34,628,588Source | 28,783,045Source | 26,405,109Source |
| Interest Expense (non-operating)USD | 66,020Source | 248,366Source | 218,705Source |
| Additional Financial Items | |||
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | -53,257Source | 148,751Source |
| General and Administrative ExpenseUSD | 6,839,712Source | 2,598,622Source | 2,915,978Source |
| Gross ProfitUSD | 17,565Source | — | — |
| Investment Income, InterestUSD | — | 5,557Source | 482Source |
| Nonoperating Income (Expense)USD | 263,824Source | 651,657Source | -912,918Source |
| Operating ExpensesUSD | 8,926,286Source | 3,091,282Source | 3,870,771Source |
| Other IncomeUSD | 47,912Source | 90,000Source | 44,500Source |
| Research and Development ExpenseUSD | 2,086,574Source | 492,660Source | 954,793Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 21,796Source | — | — |
Offerings
Registration 333-299124
Registration 333-297073
Filing attachments
ex107.htm · S-3 · 2026-09-25
Calculation of Filing Fee Tables S-3 JUPITER NEUROSCIENCES, INC. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate O…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-24
EX-99.1 5 ex99-1.htm EX-99.1 Exhibit 99.1 Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering New York, August 21, 2026 - Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offerin…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-06
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Jupiter Neurosciences, Inc. Announces Reverse Stock Split Jupiter’s common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026 JUPITER, FL, August 5, 2026 /PRNewswire/ - Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological and neurodegenerative disorders, today announced that the board of direct…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-21
EX-99.1 5 ex99-1.htm EX-99.1 Exhibit 99.1 Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering New York, May 20, 2026 - Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858. shares of common stock in a registered direct offerin…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-20
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump’s April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL - May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinic…
Read attachment ↗